drugset / Trial / NCT03142646
Safety and Efficacy Evaluation of IM19 CAR-T Cells
NaSingle-groupOpen-labelTreatment
Summary
Assessment of the Safety and Feasibility of Administering T Cells Expressing an Anti-CD19 Chimeric Antigen Receptor to Patients With CD19+ B-cell leukemia or CD19+ B-all.
Timeline
- Start
- 2016-08-30
- Primary completion
- 2018-06-01
- Completion
- 2018-10-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | IM19 | Cell therapy | — | Intravenous |
| Background | Cyclophosphamide | Other / unclassified | — | — |
| Background | Fludarabine | Small molecule | — | — |